NCT07655362尚未招募3 期
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Baxdrostat on Ventricular Remodeling
Subodh Verma2 个研究点 分布在 1 个国家目标入组 286 人开始时间: 2026年6月30日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 286
- 试验地点
- 2
- 主要终点
- Left Ventricular Mass indexed to baseline body surface area (LVMi)
研究概览
简要总结
The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at risk for heart or kidney disease.
To determine if baxdrostat improves heart structure and function, the participants will:
- take a baxdrostat or a placebo (a look-alike tablet that contains no drug) tablet once a day for 12 months
- undergo a safe and non-invasive cardiac magnetic resonance imaging scan (to measure heart mass, stiffness and function) at the beginning of the study and 12 months later
- visit the clinic for checkups and blood or urine tests 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after taking the first tablet
详细描述
The BaxREMODEL CardioLink-18 Research Study is a multicentre, prospective, randomized, double-blind, parallel research study of baxdrostat vs placebo in addition to standard-of-care in adults with a history of hypertension and either cardiovascular or cardiorenal risk factors plus evidence of left ventricular hypertrophy or increased left ventricular mass. A total of 286 individuals will be assigned (1:1) to receive either baxdrostat 2 mg or placebo QD for 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Individuals ≥18 years of age who are willing and able to provide signed informed consent
- •History of hypertension (Systolic BP >140 and <170 mmHg)
- •Serum K+ ≥3.5 and <5.0 mmol/L at Screening
- •Evidence of left ventricular (LV) hypertrophy ≤12 months prior to or at screening showing at least one (≥1) of the following:
- •Interventricular septal (IVS) thickness by echocardiography: Female ≥1.2 cm or Male ≥1.3 cm
- •Posterior wall (PW) thickness by echocardiography: Female ≥1.2 cm or Male ≥1.3 cm
- •Left ventricular mass indexed to baseline body surface area (LVMi) by echocardiography: Female >95 g⁄m^2 or Male >115 g⁄m^2
- •LVMi by cMRI: Female >68 g⁄m^2 or Male >85 g⁄m^2
- •The presence of ≥1 of the following risk factors:
- •Documented type 2 diabetes mellitus or a glycated hemoglobin (A1C) level ≥6.5%
- •Estimated glomerular filtration rate (eGFR) 45-60 mL/min/1.73m^2 at Screening
- •Urine albumin-creatinine ratio (UACR) ≥3 mg/mmol
- •IVS ≥1.4 cm
- •PW ≥1.4 cm
- •LVMi ≥105 g⁄m^2 for female and ≥125 g⁄m^2 for male individuals (by echocardiography)
- •History of HFpEF (LV ejection fraction ≥50%)
- •NT-proBNP ≥125 pg/mL (within past 6 months)
- •Female individuals who are of childbearing age can only be considered eligible if:
- •they are postmenopausal (amenorrhoeic for ≥12 months following cessation of exogenous hormonal treatment) or have had a surgical procedure (eg. hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) ≥6 months at Screening that prevents them from becoming pregnant or
- •the result of their pregnancy test at the baseline visit is negative, and they agree to use at least one highly effective and one effective contraception method to avoid pregnancy during the 30 days before randomization, throughout the research study, and for at least 30 days after taking the last dose of the assigned IP
- •Considered unsuitable by the investigator for any reason that may either place the participant at increased risk during participation or interfere with the interpretation of the study outcomes
- •Female individuals who are pregnant, or can get pregnant, are breast-feeding or are planning to breastfeed and are/will not be using at least one highly effective contraception method (see Inclusion Criteria section for definitions) during the 30 days before Randomization, throughout the research study, and for at least 30 days after taking the last dose of the assigned IP
- •Upper arm circumference <18 cm or >43 cm at Screening
- •Body mass index >40 kg/m^2 (Image quality and accurate assessment of cardiac function degrades with obesity across all imaging modalities. Although CMR-derived images are the least compromised by high body mass indexes, MRI bore sizes and table weight limits, greater safety risks [eg. thermal burns] as well as increased frequencies of claustrophobia remain major challenges.
- •Contraindication or inability to undergo CMR scan
- •Serum Na+ level <135 mmol/L at Screening
- •A1C >10% if living with T2DM during the 30 days before Randomization
- •At Screening
- •Systolic BP ≤120 mmHg
- •Heart rate >110 or <45 bpm per electrocardiogram (ECG) performed at Screening
- •eGFR <45 mL/min/1.73m^2 at Screening
- •New York Heart Association (NYHA) functional HF class IV
- •At Screening or first IP intake
- •White blood cell (WBC) count >15 X 10^9/L or absolute neutrophil count <1 X 10^9/L
- •Hemoglobin (Hb) <100 g/L and/or anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion within 60 days after screening
- •Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3X upper limits of normal (ULN) with a corresponding bilirubin >34 μmol/L unless the potential participant has a history of Gilbert syndrome
- •Medical history
- •Planned dialysis or kidney transplant during this research study
- •Adrenal insufficiency
- •Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including chronic obstructive pulmonary disease
- •Secondary causes of hypertension eg. Cushing's syndrome, aortic coarctation, renal artery stenosis, uncontrolled hyperthyroidism, untreated hyperthyroidism, hypothyroidism or pheochromocytoma
- •HF due to infiltrative cardiomyopathy (eg. sarcoid, amyloid), arrhythmogenic right ventricular (RV) cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease
- •Acute coronary syndrome, myocardial infarction, stroke, unstable angina pectoris, hypertensive encephalopathy, transient ischemic attack, or hospitalization for HF, during the 30 days before Screening
- •Persistent atrial fibrillation, left bundle branch block or any cardiac arrhythmia requiring treatment
- •Severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history
- •Clinical evidence of, or suspicion of, active infection (at the discretion of the Site Investigator)
- •Surgical history
- •Undergone a major cardiovascular surgical procedure (eg. percutaneous coronary intervention/coronary artery bypass grafting or percutaneous coronary
- •Intervention/coronary artery bypass grafting) or major endoscopic procedure (thoracoscopic or laparoscopic) during the 60 days before Randomization
- •Previous or planned coronary, carotid, or peripheral artery revascularization during the 45 days before Screening
- 另有 10 项未显示
排除标准
- 未提供
研究组 & 干预措施
Placebo
Placebo Comparator
Control treatment group
干预措施: Placebo (Drug)
Baxdrostat
Active Comparator
Active treatment group
干预措施: Baxdrostat (Drug)
结局指标
主要结局
Left Ventricular Mass indexed to baseline body surface area (LVMi)
时间窗: 12 months
Change in LVMi (g/m\^2), measured by cardiac magnetic resonance imaging (cMRI) from baseline to 12 months of treatment with baxdrostat compared to placebo.
次要结局
- Left Atrial Volume indexed to baseline body surface area (LAVi)(12 months)
- Left Ventricular Ejection Fraction (LVEF)(12 months)
- Left Ventricular End-Diastolic Volume indexed to baseline body surface area (LVEDVi)(12 months)
- Left Ventricular End-Systolic Volume indexed to baseline body surface area (LVESVi)(12 months)
- Right Ventricular Ejection Fraction (RVEF)(12 months)
- Right Ventricular End-Diastolic Volume indexed to baseline body surface area (RVEDVi)(12 months)
- Right Ventricular End-Systolic Volume indexed to baseline body surface area (RVESVi)(12 months)
研究者
Subodh Verma
Professor of Surgery and Pharmacology & Toxicology
Canadian Medical and Surgical Knowledge Translation Research Group
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A trial to learn how safe baxdrostat with dapagliflozin is and how well it works in adults with chronic kidney disease (CKD) and high blood pressureChronic kidney disease, unspecified, (2) ICD-10 Condition: I10||Essential (primary) hypertension,CTRI/2025/05/086224AstraZeneca AB5,000
招募中
3 期
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressureUncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agents, including a diuretic.
Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.2023-505499-32-00Astrazeneca AB205
招募中
3 期
A trial to learn how safe baxdrostat is and how well it works in adults with primary aldosteronismPrimary Aldosteronism defined by excess aldosterone secretion2025-520740-16-00AstraZeneca AB49
招募中
3 期
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adults with chronic kidney disease (CKD) and high blood pressureChronic kidney disease (CKD) and hypertension.2023-506460-14-00Astrazeneca AB1,310
已完成
1 期
A trial to learn how baxdrostat affects the heartbeat in healthy participantsTreatment-resistant hypertensionPrimary aldosteronismUncontrolled hypertension2023-506108-23-00Astrazeneca AB28